Company: PSTV
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047698
Chunk: 108

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1A
Chunk 108
---
 to which we have rights under valid and enforceable patents or trade secrets that cover these activities.  

The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage.  For example:

51 

•we, NanoTx, or UTHSCSA, as the case may be, might not have been the first to file patent applications for REYOBIQ™ or 188RNL-BAM; 

•we, or Biocept, as the case may be, might not have been the first to file patent applications for the CNSideTM Platform;

•it is possible that our pending patent applications will not result in issued patents;

•it is possible that there are dominating patents to our product candidates of which we are not aware;

•it is possible that there are prior public disclosures that could invalidate our patents, of which we are not aware;

•it is possible that others may circumvent our patents;

•it is possible that there are unpublished applications or patent applications maintained in secrecy that may later issue with claims covering our product candidates or technology similar to ours;

•the claims of our patents or patent applications, if and when issued, may not cover our system or products, or our system or product candidates;

•our owned or in-licensed issued patents may not provide us with any competitive advantages, or may be narrowed in scope, be held invalid or unenforceable as a result of legal administrative challenges by third parties;

•others may be able to make or use compounds that are the same or similar to the REYOBIQ™ or 188RNL-BAM product candidates but that are not covered by the claims of our patents; 

•we may not be able to detect infringement against our patents, which may be especially difficult for manufacturing processes or formulation patents, such as the patents/applications related to REYOBIQ™ or 188RNL-BAM;

•the API used in REYOBIQ™, 186-Re, is routinely produced in nuclear reactors or at a particle accelerator and is commercially available as 186-Re Sulfide for isotropic radiation synovectomy of medium sized joints and in developing countries as 186-Re-HEDP for bone pain palliation; 

•we may not develop additional proprietary technologies for which we can obtain patent protection; or

•the patents of others may have an adverse effect on our business.

The patent positions of pharmaceutical, biopharmaceutical and medical